These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 28433474)

  • 61. Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and Morvan's syndrome.
    Díaz-Manera J; Rojas-García R; Gallardo E; Juárez C; Martínez-Domeño A; Martínez-Ramírez S; Dalmau J; Blesa R; Illa I
    Nat Clin Pract Neurol; 2007 Jul; 3(7):405-10. PubMed ID: 17611489
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Eculizumab versus rituximab in generalised myasthenia gravis.
    Nelke C; Schroeter CB; Stascheit F; Pawlitzki M; Regner-Nelke L; Huntemann N; Arat E; Öztürk M; Melzer N; Mergenthaler P; Gassa A; Stetefeld H; Schroeter M; Berger B; Totzeck A; Hagenacker T; Schreiber S; Vielhaber S; Hartung HP; Meisel A; Wiendl H; Meuth SG; Ruck T
    J Neurol Neurosurg Psychiatry; 2022 May; 93(5):548-554. PubMed ID: 35246490
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Refractory myasthenia gravis with good response to rituximab. Report of one case].
    Suárez H F; Urrutia E D
    Rev Med Chil; 2020 Jul; 148(7):1031-1033. PubMed ID: 33399689
    [No Abstract]   [Full Text] [Related]  

  • 64. A single low-dose rituximab infusion in severe chronic refractory myasthenia gravis in resource-limited settings.
    Heckmann JM
    J Neurol Sci; 2022 Nov; 442():120394. PubMed ID: 36057244
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Temporal correlation between serum CH
    Yanagidaira M; Nishida Y; Yokota T
    Clin Neurol Neurosurg; 2020 Feb; 189():105630. PubMed ID: 31830679
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Long-Term Efficacy and Safety of Low-Dose Rituximab in Patients with Refractory Myasthenia Gravis.
    Ren J; Wang J; Liu R; Jin Y; Guo J; Yao Y; Luo J; Hao H; Gao F
    Eur Neurol; 2023; 86(6):387-394. PubMed ID: 37778340
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Myasthenia gravis: new therapeutic approaches based on pathophysiology.
    Lewis RA
    J Neurol Sci; 2013 Oct; 333(1-2):93-8. PubMed ID: 23938353
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab.
    Hain B; Jordan K; Deschauer M; Zierz S
    Muscle Nerve; 2006 Apr; 33(4):575-80. PubMed ID: 16323216
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Rituximab as induction therapy in refractory myasthenia gravis: 18 month follow-up study.
    Singh N; Goyal V
    J Neurol; 2019 Jul; 266(7):1596-1600. PubMed ID: 30919039
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis.
    Baek WS; Bashey A; Sheean GL
    J Neurol Neurosurg Psychiatry; 2007 Jul; 78(7):771. PubMed ID: 17575026
    [No Abstract]   [Full Text] [Related]  

  • 71. Three cases of myasthenia gravis from one family with variations in clinical features and serum antibodies.
    Chen Y; Wang W; Wei D; Yang L
    Neuromuscul Disord; 2012 Mar; 22(3):286-8. PubMed ID: 22082588
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Myasthenia gravis].
    Fleury MC; Tranchant C
    Rev Prat; 2008 Dec; 58(20):2217-24. PubMed ID: 19209651
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Resistant myasthenia gravis and rituximab: A monocentric retrospective study of 28 patients.
    Afanasiev V; Demeret S; Bolgert F; Eymard B; Laforêt P; Benveniste O
    Neuromuscul Disord; 2017 Mar; 27(3):251-258. PubMed ID: 28082209
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Allogeneic hematopoietic cell transplantation for refractory myasthenia gravis.
    Strober J; Cowan MJ; Horn BN
    Arch Neurol; 2009 May; 66(5):659-61. PubMed ID: 19433668
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study.
    Siddiqi ZA; Nowak RJ; Mozaffar T; O'Brien F; Yountz M; Patti F;
    Muscle Nerve; 2021 Dec; 64(6):662-669. PubMed ID: 34590717
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Long-Term Remission With Low-Dose Rituximab in Myasthenia Gravis: A Retrospective Study.
    Castiglione JI; Rivero AD; Barroso F; Brand P; Lautre A; Kohler AA
    J Clin Neuromuscul Dis; 2022 Sep; 24(1):18-25. PubMed ID: 36005470
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effect of low-dose rituximab treatment on T- and B-cell lymphocyte imbalance in refractory myasthenia gravis.
    Jing S; Lu J; Song J; Luo S; Zhou L; Quan C; Xi J; Zhao C
    J Neuroimmunol; 2019 Jul; 332():216-223. PubMed ID: 31100692
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Unusual association of amyotrophic lateral sclerosis and myasthenia gravis: A dysregulation of the adaptive immune system?
    Del Mar Amador M; Vandenberghe N; Berhoune N; Camdessanché JP; Gronier S; Delmont E; Desnuelle C; Cintas P; Pittion S; Louis S; Demeret S; Lenglet T; Meininger V; Salachas F; Pradat PF; Bruneteau G
    Neuromuscul Disord; 2016 Jun; 26(6):342-6. PubMed ID: 27102004
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Rituximab in Newly Diagnosed Generalized Myasthenia Gravis: A New Treatment Paradigm?
    Chuquilin M; Barohn R
    JAMA Neurol; 2022 Nov; 79(11):1100-1102. PubMed ID: 36121665
    [No Abstract]   [Full Text] [Related]  

  • 80. Memory B Cells Predict Relapse in Rituximab-Treated Myasthenia Gravis.
    Ruetsch-Chelli C; Bresch S; Seitz-Polski B; Rosenthal A; Desnuelle C; Cohen M; Brglez V; Ticchioni M; Lebrun-Frenay C
    Neurotherapeutics; 2021 Apr; 18(2):938-948. PubMed ID: 33768513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.